Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Monoclonal anti‐SARS‐CoV‐2 immunoglobulins represent a treatment option for COVID‐19. However, their production in mammalian cells is not scalable to meet the global demand. Single‐domain (VHH) antibodies (also called nanobodies) provide an alternative suitable for microbial production. Using alpaca...

Descripción completa

Detalles Bibliográficos
Autores principales: Güttler, Thomas, Aksu, Metin, Dickmanns, Antje, Stegmann, Kim M., Gregor, Kathrin, Rees, Renate, Taxer, Waltraud, Rymarenko, Oleh, Schünemann, Jürgen, Dienemann, Christian, Gunkel, Philip, Mussil, Bianka, Krull, Jens, Teichmann, Ulrike, Groß, Uwe, Cordes, Volker C, Dobbelstein, Matthias, Görlich, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420576/
https://www.ncbi.nlm.nih.gov/pubmed/34302370
http://dx.doi.org/10.15252/embj.2021107985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420576/
https://www.ncbi.nlm.nih.gov/pubmed/34302370
http://dx.doi.org/10.15252/embj.2021107985

Ejemplares similares